Tilray Brands, Inc. (TLRY)
NASDAQ: TLRY · Real-Time Price · USD
1.710
+0.130 (8.23%)
At close: Oct 7, 2025, 4:00 PM EDT
1.700
-0.010 (-0.58%)
After-hours: Oct 7, 2025, 7:59 PM EDT
Tilray Brands Revenue
In the fiscal year ending May 31, 2025, Tilray Brands had annual revenue of $821.31M with 4.10% growth. Tilray Brands had revenue of $224.54M in the quarter ending May 31, 2025, a decrease of -2.33%.
Revenue (ttm)
$821.31M
Revenue Growth
+4.10%
P/S Ratio
1.85
Revenue / Employee
$288,990
Employees
2,842
Market Cap
1.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
May 31, 2025 | 821.31M | 32.37M | 4.10% |
May 31, 2024 | 788.94M | 161.82M | 25.80% |
May 31, 2023 | 627.12M | -1.25M | -0.20% |
May 31, 2022 | 628.37M | 115.29M | 22.47% |
May 31, 2021 | 513.09M | 107.76M | 26.59% |
May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TLRY News
- 1 day ago - Tilray Brands Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
- 1 day ago - Tilray stock price forecast ahead of earnings: buy, sell, or hold? - Invezz
- 7 days ago - Tilray stock price forecast as it faces major headwinds - Invezz
- 7 days ago - Best Canadian Cannabis Stocks to Watch for Growth and Opportunity - MarijuanaStocks
- 7 days ago - Wall Street Breakfast Podcast: Weed Stocks Light Up - Seeking Alpha
- 7 days ago - Tilray, a Global Leader in Medical Cannabis, Announces Expansion of Premium Craft Cannabis Production at its Advanced EU-GMP Facility in Germany; Tilray Medical Enhances Tilray Craft Cannabis Portfolio with New Patient-Centered Offerings - GlobeNewsWire
- 8 days ago - Cannabis stocks soar after Trump shares video promoting drug's use for seniors - The Guardian
- 8 days ago - Cannabis stocks surge after Trump posts video touting Medicare coverage for CBD - New York Post